A new phase 2 clinical trial of multiple therapies to treat patients with severe asthma, specifically focusing on personalized therapies based on genetics, family history, lifestyle and environmental factors, is currently underway.
The phase 2, multicenter Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) study will involve 650 adult and 150 adolescent volunteers aged 12 years and older with poorly controlled asthma or frequent asthma exacerbations at 30 sites in the U.S., Canada and the U.K., according to a press release issued by the Cleveland Clinic.
The trial is sponsored by the NHLBI and is enrolling patients at Cleveland Clinic and University Hospitals Rainbow Babies & Children’s Hospital, according to the release.
The aim is to provide personalized therapies based on an individual patient’s unique genetics, familial history, lifestyle behavior and environmental factors to allow customized treatments and adjustments based on how each patient responds.
This study will assess the effectiveness of six experimental asthma therapies: medium-chain triglyceride supplementation, clazakizumab, broncho-vaxom, imatinib mesylate, cavosonstat and itacitinib.
During the study, patients will record their asthma symptoms and perform tests to aid researchers in understanding the specific type of severe asthma they may have. Based on these reports, adults may receive two to five different asthma therapies and pediatric patients may receive up to three different therapies.
“Asthma is a complex disease with variable severity and response to treatment. Our aim with this multicenter study is to enhance our ability to individualize treatments to better care for our patients with asthma,” Serpil Erzurum, MD, chief research and academic officer in the department of inflammation and immunity at Cleveland Clinic, said in the related press release. “If we can better understand individual factors such as how our genes and diet affect asthma, we can more accurately choose treatment or prevention strategies that will work best for each patient.”